195 related articles for article (PubMed ID: 38542151)
1. Elucidation of the Role of the Epigenetic Regulatory Mechanisms of PI3K/Akt/mTOR Signaling Pathway in Human Malignancies.
Mohite R; Doshi G
Curr Cancer Drug Targets; 2024; 24(3):231-244. PubMed ID: 37526459
[TBL] [Abstract][Full Text] [Related]
2. Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer.
Tufail M; Wan WD; Jiang C; Li N
Chem Biol Interact; 2024 Jun; 396():111055. PubMed ID: 38763348
[TBL] [Abstract][Full Text] [Related]
3. Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?
Liu Y; Sun Q; Wei X
Expert Opin Ther Targets; 2024 Mar; 28(3):221-232. PubMed ID: 38646899
[TBL] [Abstract][Full Text] [Related]
4. PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer.
Yakkala PA; Naaz F; Shafi S; Kamal A
Expert Opin Ther Targets; 2024 Mar; 28(3):159-177. PubMed ID: 38497299
[TBL] [Abstract][Full Text] [Related]
5. A Contemporary Review on the Critical Role of Nonsteroidal Anti-inflammatory Agents in Colorectal Cancer Therapy.
Sarabi PZ; Moradi M; Bagheri M; Khalili MR; Moradifard S; Jamialahmadi T; Ghasemi F; Sahebkar A
Anticancer Agents Med Chem; 2024; 24(8):559-570. PubMed ID: 38275052
[TBL] [Abstract][Full Text] [Related]
6. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam PD; Are C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.
Sanaei MJ; Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Shahrokh S; Zali MR; Bashash D
J Cell Physiol; 2022 Mar; 237(3):1720-1752. PubMed ID: 34897682
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D; Brown VI; Grupp SA; Teachey DT
Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
[TBL] [Abstract][Full Text] [Related]
9. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
[TBL] [Abstract][Full Text] [Related]
10. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
Narayanankutty A
Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
[TBL] [Abstract][Full Text] [Related]
11. B7-H4 facilitates proliferation and metastasis of colorectal carcinoma cell through PI3K/Akt/mTOR signaling pathway.
Li C; Zhan Y; Ma X; Fang H; Gai X
Clin Exp Med; 2020 Feb; 20(1):79-86. PubMed ID: 31664539
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer: Review of signaling pathways and associated therapeutic strategies.
Leiphrakpam PD; Rajappa SJ; Krishnan M; Batra R; Murthy SS; Are C
J Surg Oncol; 2023 Jun; 127(8):1277-1295. PubMed ID: 37222698
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer statistics, 2023.
Siegel RL; Wagle NS; Cercek A; Smith RA; Jemal A
CA Cancer J Clin; 2023; 73(3):233-254. PubMed ID: 36856579
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
